Skip to main content
NYSEAMERICAN:DXR

Daxor Competitors

$8.99
-0.06 (-0.66 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.74
$9.88
50-Day Range
$12.41
$13.20
52-Week Range
$8.74
$24.08
Volume26,564 shs
Average Volume9,858 shs
Market Capitalization$34.96 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.94

Competitors

Daxor (NYSEAMERICAN:DXR) Vs. PDEX, ISR, XAIR, VERO, LYRA, and EDTXF

Should you be buying DXR stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Daxor, including Pro-Dex (PDEX), Isoray (ISR), Beyond Air (XAIR), Venus Concept (VERO), Lyra Therapeutics (LYRA), and Spectral Medical (EDTXF).

Pro-Dex (NASDAQ:PDEX) and Daxor (NYSEAMERICAN:DXR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.

Insider & Institutional Ownership

15.1% of Pro-Dex shares are owned by institutional investors. Comparatively, 5.0% of Daxor shares are owned by institutional investors. 40.8% of Pro-Dex shares are owned by insiders. Comparatively, 77.9% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Pro-Dex and Daxor's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pro-Dex$34.83 million3.48$6.11 millionN/AN/A
DaxorN/AN/AN/AN/AN/A

Pro-Dex has higher revenue and earnings than Daxor.

Profitability

This table compares Pro-Dex and Daxor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pro-Dex17.34%33.84%21.11%
DaxorN/AN/AN/A

Risk & Volatility

Pro-Dex has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Daxor has a beta of -0.94, meaning that its stock price is 194% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Pro-Dex and Daxor, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pro-Dex0000N/A
Daxor00203.00

Daxor has a consensus price target of $21.50, indicating a potential upside of 139.15%. Given Daxor's higher probable upside, analysts clearly believe Daxor is more favorable than Pro-Dex.

Summary

Pro-Dex beats Daxor on 6 of the 9 factors compared between the two stocks.

Isoray (NYSEAMERICAN:ISR) and Daxor (NYSEAMERICAN:DXR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Insider & Institutional Ownership

7.7% of Isoray shares are owned by institutional investors. Comparatively, 5.0% of Daxor shares are owned by institutional investors. 3.8% of Isoray shares are owned by insiders. Comparatively, 77.9% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Isoray and Daxor's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Isoray$9.68 million11.41$-3,450,000.00($0.05)-15.65
DaxorN/AN/AN/AN/AN/A

Daxor has lower revenue, but higher earnings than Isoray.

Profitability

This table compares Isoray and Daxor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Isoray-34.32%-58.76%-38.66%
DaxorN/AN/AN/A

Volatility and Risk

Isoray has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, Daxor has a beta of -0.94, indicating that its share price is 194% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Isoray and Daxor, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Isoray01402.80
Daxor00203.00

Isoray presently has a consensus target price of $1.9625, indicating a potential upside of 150.86%. Daxor has a consensus target price of $21.50, indicating a potential upside of 139.15%. Given Isoray's higher possible upside, research analysts plainly believe Isoray is more favorable than Daxor.

Beyond Air (NASDAQ:XAIR) and Daxor (NYSEAMERICAN:DXR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Insider & Institutional Ownership

21.4% of Beyond Air shares are owned by institutional investors. Comparatively, 5.0% of Daxor shares are owned by institutional investors. 18.1% of Beyond Air shares are owned by insiders. Comparatively, 77.9% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Beyond Air and Daxor's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beyond Air$1.39 million73.25$-19,940,000.00($1.53)-3.25
DaxorN/AN/AN/AN/AN/A

Daxor has lower revenue, but higher earnings than Beyond Air.

Profitability

This table compares Beyond Air and Daxor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Beyond AirN/A-152.25%-99.76%
DaxorN/AN/AN/A

Volatility and Risk

Beyond Air has a beta of -0.66, indicating that its share price is 166% less volatile than the S&P 500. Comparatively, Daxor has a beta of -0.94, indicating that its share price is 194% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Beyond Air and Daxor, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Beyond Air00303.00
Daxor00203.00

Beyond Air presently has a consensus target price of $11.00, indicating a potential upside of 121.33%. Daxor has a consensus target price of $21.50, indicating a potential upside of 139.15%. Given Daxor's higher possible upside, analysts plainly believe Daxor is more favorable than Beyond Air.

Venus Concept (NASDAQ:VERO) and Daxor (NYSEAMERICAN:DXR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Insider & Institutional Ownership

38.2% of Venus Concept shares are owned by institutional investors. Comparatively, 5.0% of Daxor shares are owned by institutional investors. 47.0% of Venus Concept shares are owned by insiders. Comparatively, 77.9% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Venus Concept and Daxor's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venus Concept$110.41 million0.88$-40,620,000.00($4.77)-0.38
DaxorN/AN/AN/AN/AN/A

Daxor has lower revenue, but higher earnings than Venus Concept.

Profitability

This table compares Venus Concept and Daxor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Venus Concept-104.71%-132.46%-41.17%
DaxorN/AN/AN/A

Volatility and Risk

Venus Concept has a beta of 2.62, indicating that its share price is 162% more volatile than the S&P 500. Comparatively, Daxor has a beta of -0.94, indicating that its share price is 194% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Venus Concept and Daxor, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Venus Concept01402.80
Daxor00203.00

Venus Concept presently has a consensus target price of $5.10, indicating a potential upside of 183.33%. Daxor has a consensus target price of $21.50, indicating a potential upside of 139.15%. Given Venus Concept's higher possible upside, research analysts plainly believe Venus Concept is more favorable than Daxor.

Lyra Therapeutics (NASDAQ:LYRA) and Daxor (NYSEAMERICAN:DXR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Insider & Institutional Ownership

59.3% of Lyra Therapeutics shares are owned by institutional investors. Comparatively, 5.0% of Daxor shares are owned by institutional investors. 77.9% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Lyra Therapeutics and Daxor, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lyra Therapeutics00403.00
Daxor00203.00

Lyra Therapeutics presently has a consensus target price of $26.00, indicating a potential upside of 248.53%. Daxor has a consensus target price of $21.50, indicating a potential upside of 139.15%. Given Lyra Therapeutics' higher possible upside, research analysts plainly believe Lyra Therapeutics is more favorable than Daxor.

Profitability

This table compares Lyra Therapeutics and Daxor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lyra TherapeuticsN/AN/AN/A
DaxorN/AN/AN/A

Valuation & Earnings

This table compares Lyra Therapeutics and Daxor's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lyra TherapeuticsN/AN/AN/AN/AN/A
DaxorN/AN/AN/AN/AN/A

Summary

Lyra Therapeutics beats Daxor on 3 of the 4 factors compared between the two stocks.

Spectral Medical (OTCMKTS:EDTXF) and Daxor (NYSEAMERICAN:DXR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Institutional & Insider Ownership

5.0% of Daxor shares are held by institutional investors. 77.9% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Spectral Medical and Daxor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spectral Medical-360.71%-497.60%-89.50%
DaxorN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and price targets for Spectral Medical and Daxor, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spectral Medical0000N/A
Daxor00203.00

Daxor has a consensus price target of $21.50, indicating a potential upside of 139.15%. Given Daxor's higher probable upside, analysts clearly believe Daxor is more favorable than Spectral Medical.

Risk & Volatility

Spectral Medical has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, Daxor has a beta of -0.94, suggesting that its stock price is 194% less volatile than the S&P 500.

Earnings & Valuation

This table compares Spectral Medical and Daxor's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spectral Medical$2.17 million43.64$-3,660,000.00N/AN/A
DaxorN/AN/AN/AN/AN/A

Daxor has lower revenue, but higher earnings than Spectral Medical.

Summary

Daxor beats Spectral Medical on 7 of the 9 factors compared between the two stocks.


Daxor Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Pro-Dex logo
PDEX
Pro-Dex
0.7$33.20-1.2%$121.11 million$34.83 million26.97Earnings Announcement
Isoray logo
ISR
Isoray
1.4$0.78-5.1%$110.46 million$9.68 million-15.65Earnings Announcement
News Coverage
Beyond Air logo
XAIR
Beyond Air
1.7$4.97-3.0%$101.82 million$1.39 million-3.17Gap Up
Venus Concept logo
VERO
Venus Concept
1.9$1.80-0.6%$97.33 million$110.41 million-0.54Upcoming Earnings
Lyra Therapeutics logo
LYRA
Lyra Therapeutics
1.5$7.46-6.7%$96.70 millionN/A0.00Earnings Announcement
Analyst Upgrade
Spectral Medical logo
EDTXF
Spectral Medical
0.6$0.40-0.1%$94.74 million$2.17 million-13.33Upcoming Earnings
Gap Up
Avinger logo
AVGR
Avinger
1.4$0.91-11.0%$86.77 million$9.13 million-0.69
LENSAR logo
LNSR
LENSAR
1.4$7.57-2.5%$82.76 millionN/A0.00
Nephros logo
NEPH
Nephros
2.0$8.02-0.4%$79.90 million$10.33 million-17.43Gap Up
SANUWAVE Health logo
SNWV
SANUWAVE Health
1.4$0.15-0.0%$72.89 million$1.03 million0.00Upcoming Earnings
NEPHD
Nephros
0.6$8.02-0.4%$61.53 million$5.69 million-14.85High Trading Volume
Gap Up
Delcath Systems logo
DCTH
Delcath Systems
1.9$9.74-2.1%$60.89 million$1.58 million-0.01Earnings Announcement
Analyst Report
AIT Therapeutics logo
AITB
AIT Therapeutics
0.6$4.97-3.0%$52.59 millionN/A-1.65High Trading Volume
Gap Up
Sensus Healthcare logo
SRTS
Sensus Healthcare
1.4$3.18-5.7%$52.44 million$27.26 million-7.57Analyst Downgrade
STRATA Skin Sciences logo
SSKN
STRATA Skin Sciences
1.5$1.48-2.0%$50.03 million$31.59 million-10.57Earnings Announcement
Neovasc logo
NVCN
Neovasc
1.4$0.74-4.1%$49.93 million$2.09 million-0.23Gap Up
Plus Therapeutics logo
PSTV
Plus Therapeutics
1.5$2.04-6.4%$43.06 million$7 million-2.02
Motus GI logo
MOTS
Motus GI
1.5$0.92-6.5%$43.03 million$110,000.00-1.30
Hancock Jaffe Laboratories logo
HJLI
Hancock Jaffe Laboratories
0.5$5.02-4.0%$42.69 million$30,000.000.00
INVO Bioscience logo
INVO
INVO Bioscience
1.1$3.86-2.1%$40.22 million$1.48 million-4.05Upcoming Earnings
InspireMD logo
NSPR
InspireMD
1.3$4.42-7.9%$34.95 million$3.72 million-3.51Earnings Announcement
Sintx Technologies logo
SINT
Sintx Technologies
1.3$1.32-5.3%$32.58 million$690,000.00-0.56
Arch Therapeutics logo
ARTH
Arch Therapeutics
1.2$0.12-8.2%$29.00 millionN/A0.00Upcoming Earnings
Vivos logo
RDGL
Vivos
0.0$0.08-0.0%$26.19 million$10,000.000.00Gap Up
Obalon Therapeutics logo
OBLN
Obalon Therapeutics
0.5$2.59-28.2%$25.95 million$3.28 million-1.26Gap Down
InVivo Therapeutics logo
NVIV
InVivo Therapeutics
0.7$0.62-9.7%$21.24 millionN/A0.00Gap Up
Aethlon Medical logo
AEMD
Aethlon Medical
1.4$1.54-7.8%$18.68 million$650,000.00-0.82
LLIT
Lianluo Smart
0.5$7.15-15.5%$15.81 million$380,000.000.00High Trading Volume
Gap Up
Dynatronics logo
DYNT
Dynatronics
1.3$1.03-2.9%$15.42 million$53.41 million-2.57News Coverage
Gap Up
ACAI
Safeplus International
0.0$1.79-22.3%$11.79 millionN/A0.00Gap Down
Ra Medical Systems logo
RMED
Ra Medical Systems
1.3$3.55-10.4%$11.56 million$7.20 million-0.08Earnings Announcement
High Trading Volume
Gap Down
Biostage logo
BSTG
Biostage
0.6$1.15-8.7%$10.80 millionN/A-1.74
NeuroMetrix logo
NURO
NeuroMetrix
0.6$2.72-7.0%$10.34 million$9.27 million0.00
BIPHD
Safeplus International
0.0$1.79-22.3%$9.64 millionN/A0.00Gap Down
NEMD
iNeedMD
0.0$0.20-0.0%$9.60 millionN/A0.00
Ophectra Real Estate and Investments logo
MTTCF
Ophectra Real Estate and Investments
0.0$0.78-2.6%$9.54 millionN/A0.00Gap Down
ECIA
Encision
0.7$0.57-5.3%$6.60 million$7.67 million-57.00Gap Down
Cellect Biotechnology logo
APOP
Cellect Biotechnology
0.6$2.57-2.7%$5.76 millionN/A-1.43Upcoming Earnings
H-CYTE logo
HCYT
H-CYTE
0.0$0.03-0.6%$4.65 million$8.35 million-0.11Upcoming Earnings
RGIN
Regenicin
0.5$0.03-0.0%$4.31 millionN/A0.00Gap Up
CVR Medical logo
CRRVF
CVR Medical
0.0$0.03-33.8%$4.06 millionN/A-2.99Gap Down
Calmare Therapeutics logo
CTTC
Calmare Therapeutics
0.4$0.08-35.2%$3.33 millionN/A0.00High Trading Volume
MDIT
Medite Cancer Diagnostics
0.8$0.02-58.9%$2.38 millionN/A0.00Gap Up
LENSF
Presbia
0.3$0.13-61.5%$2.24 million$20,000.000.00Gap Up
HDII
Hypertension Diagnostics
0.7$0.01-0.0%$2.09 millionN/A0.00
DXTRQ
Dex Liquidating
0.0$0.03-0.0%$1.45 millionN/A0.00
ASNB
EKIMAS
0.8$0.02-31.4%$757,000.00$3.35 million2.60Gap Down
TearLab logo
TEAR
TearLab
0.6$0.06-1.9%$754,000.00$22.66 million-0.13Gap Down
UAHC
United American Healthcare
0.5$0.04-0.0%$642,000.00N/A0.00
Endologix logo
ELGXQ
Endologix
0.1$0.02-0.0%$411,000.00$143.37 million-0.01Upcoming Earnings
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.